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Summary: The oral pancreatic function test with N-benzoyl-Z,-tyrosyl-p-aminobenzoic acid was performed on
24 healthy test subjects, and its toxicity was examined. Eight patients with restricted renal function and known
renal disease were also investigated. The pancreatic function test and the same procedure using free p-amino-benzoic
acid were performed at 2—3-day intervals.
During all the investigations with the pancreatic function test, no clinical side effects were observed. All para-
meters investigated at all the test times fell within the normal range. No toxicity of N-benzoyl-Z,-tyrosyl-p-amino-
benzoic acid could be found. The excretion ofp-aminobenzoic acid after administration of N-benzoyl-£-tyrosyl-p-
aminobenzoic acid was greatly reduced in all patients with restricted renal function. Four of eight patients also
showed essentially no increase in excretion rate when free p-aminobenzoic acid was given instead of the pep tide. It
is therefore not possible to correct the pancreatic function test results in patients with renal insufficiency by calculat-
ing the ratio of p-aminobenzoic acid excretion after peptide intake to that after free p-aminobenzoic acid ingestion.
Adequate renal function is therefore a prerequisite for the pancreatic function test.
Der orale Pankreas-Funktions-Test mittels N-Benzoyl-L-tyrosyl-p-aminobenzoesäure:
Akute Toxizität und Beeinflussung durch die Nierenfunktion
Zusammenfassung: Der orale Pankreas-Funktions-Test mittels N-Benzoyl-Z,-tyrosyl-p-aminobenzoesäure wurde an
24 gesunden Testpersonen durchgeführt und es wurde dabei nach toxischen Effekten gesucht. Acht Patienten mit
eingeschränkter Nierenfunktion wurde außer dem Testsubstrat auch freie p-Aminobenzoesäure unter gleichen Bedin-
gungen in 2—3-tägigem Abstand verabreicht.
Während der ganzen Prüfperiode mit dem Pankreas-Funktions-Test wurden keine klinischen Nebenwirkungen beob-
achtet. Alle zu den verschiedenen Testzeiten gemessenen Größen fielen in den Normalbereich und keine toxischen Ef-
fekte konnten festgestellt werden. Die Ausscheidung an p-Aminobenzoesäure war deutlich geringer bei allen Patien-
ten mit Niereninsuffizienz. Vier dieser acht Patienten zeigten nach Verabreichung von freier p-Aminobenzoesäure
keine wesentlich höhere Ausscheidung von p-Aminobenzoesäure als nach Einnahme des Peptids. Somit ist es nicht
möglieh, die Pankreas-Funktions-Test-Resultate von niereninsuffizienten Patienten mit Hilfe einer solchen Relation
zu korrigieren. Adäquate Nierenfunktion ist also eine notwendige Voraussetzung für einen aussagekräftigen Pankreas-
Funktions-Test.
Introduction is absorbed, partially metabolized in the liver, and
excreted in the urine. The amount of p-aminobenzoic
In 1972 Imondiet al. (1) reported successful experi- acid eliminated in the urine during a given period serves
merits in animals with a new oral function test. The as a measure of exocrine pancreatic secretion. The
results were later confirmed in monkeys with metabolic- pancreatic function test has also been applied to humans
ally induced pancreatic insufficiency (2). The test is since that time (3), and on the basis of available reports
based on the chymotrypsin-specific cleavage of the it seems capable of fulfilling the expectations suggested
orally administered peptide, N-benzoyl-i-tyrosyl-p- by a screening procedure (4-8). The test is generally
aminobenzoic acid. The p-aminobenzpic acid liberated well tolerated. Till now no toxic side effects have been
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found (7). However, a systematic toxicity study has
not previously been reported in detail (3—8).
Since p-aminohippuric acid, a metabolite of p-amino-
benzoic acid, is used to test renal clearance, it would be
expected that the excretion of p-aminobenzoic acid
would be reduced after taking this peptide in the case of
renal disease. There are no test results till now, which
would permit evaluation of the pancreatic function test
in relation to renal function.
The goal of the present investigation was to perform a
systematic acute toxicity test in humans, and also to
investigate the effect of renal function on the pancreatic
function test.
Materials and Methods
Investigation of the acute toxicity
of N-benzoyKL-tyrosyl-p-aminobenzoic acid
Test subjects
Twenty-four healthy volunteers subjected themselves to the
Lundh test and the oral pancreatic function test with N-benzoyl-
/,-tyrosyl-p-aminobenzoic acid, and to the toxicity test. None
of the individuals had pancreatic disease. They denied ex-
cessive alcohol intake. Age and sex are presented in table 1.
Tab. 1. Acute toxicity of N-benzoyl-Z,-tyrosyl-p-aminobenzoic
acid: Basic data of persons tested.
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Sex
6
d
d
d
d
d
d
d
d
d
9
d
d
d
d
d
d
d
d
d
9
9
9
d
Age
(a)
26
26
27
27
26
27
25
23
26
26
25
26
24
26
27
28
26
32
38
25
25
18
21
22
Lundh test1)
(Trypsin,
MmolH-Vl-s)
145.8
295.8
583.3
258.3
200.0
-
375.0
195.8
58.3
366.7
495.8
179.2
325.0
287.5
275.0
—
345.8
254.2
366.7
195.8
187.5
325.0
141.7
-
Pancreatic func-
tion test2)
(p-aminobenzoic
acid excretion
as % of the
applied dose)
67.5
66.2
67.5
69.8
76.8
61.1
70.0
61.2
62.5
65.4
77.5
49.2
62.0
64.0
62.3
63.4
62.1
72.7
52.1
72.7 '
65.2
47.0
67.0
58.4
*) normal > 147 μιηοΐ H+/1 · s, border-line 100-
147 μιηοΐ H+/1 - s, abnormal < 100 Mmol H*/l · s.
2) normal > 47%.
Test procedure
The Lundh test was first carried out in the test subjects for the
sake of comparison and to confirm intact pancreatic function.
About 1 week later the pancreatic function test was performed,
with 4 blood sample collections and urine examinations. The
first blood sample was taken with the patient fasting prior to
ingestion of l g of N-benzoyl^tyrosyl^aminobenzoic acid
sodium salt and the other 3 at 6 hours, 24 hours, and 48 hours
after ingestion of the peptide. Each blood sample was examined
for the following parameters: hemoglobin, erythrocyte count,
leukocyte count, differential white blood cell count; bilirubin,
alkaline phosphatase, serum glutamate-oxalacetate transaminase,
serum glutamate-pyruvate transaminase, prothrombin; urea,
creatinine, sodium, potassium, calcium; serum amylase and
blood sugar. A urine sample was also examined with the first
and second blood samples. The urine samples were examined
for pH, protein, glucose, ketone bodies, urobilinogen, urine
lactate dehydrogenase, and sediment.
In six subjects ("controls") recruited from among the test
subjects (table 1: Nos 1, 2,11, 15,16, 24), blood was taken
in the fasting state and again 6 hours later. Urine was examined
under the test conditions (fasting, equal liquid intake, avoidance
of all drugs), but without administration of the peptide, in
accordance with the conditions for the toxicity test. This was
done to eliminate any artefacts in the toxicity test due solely to
water intake.
Effect of renal function on the pancreatic function test
Patients
Examinations were performed on eight hospitalized patients in
the Nephrology Department of the Kantonsspital Basel. These
patients had reduced function with known chronic renal disease.
The patients were told in detail about the study by their
physicians and signed an "informed consent" formu Table 2
provides information on the age, sex, diagnosis, and renal func-
tion in these patients.
Control group
The Lundh test and the pancreatic function test results of 13
patients with demonstrably intact renal function were used as
controls. The age, sex, diagnoses, and results of the Lundh test
and the pancreatic function test are presented in table 3.
Test procedure
At intervals of at least 48 hours, but not more than 72 hours,
the pancreatic function test and the same procedure with free
p-aminobenzoic acid were carried out on the same patient. The
Lundh test was performed at intervals of no more than 2 weeks
before or after the two tests. Between the pancreatic function
test and the intake of free p-amino-benzoic acid the serum
creatinine and the creatinine clearance were determined. How-
ever, it proved impossible to perform the Lundh test in three of
the patients because of their age, their serious primary illness, or
a lack of cooperation.
Methods
Pancreatic function test
The pancreatic function test was performed as previously
described (7).
Examination with free p-aminobenzoic acid
The patients with confirmed renal insufficiency were given
320 mg of p-aminobenzoic acid orally with 150 ml of water.
The collection of control and 6-hour urine took place in the
same manner as with the pancreatic function test.
Lundh test
The procedure of the Lundh test was described earlier (9-11).
Mean trypsin activities of 100 Mmol H*/l · s are considered ab-
normal while those of 100-147 μήιοί H+/1 · s are regarded as
borderline values (12).
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Tab. 2. Results of the several tests in patients with renal insufficiency.
Name Sex
G.M. 9
Sen. A. d
Z.L. ό
W.E. d
St. M. d
P.L. d
S.T. d
J.M. 9
Age
(a)
60
45
39
55
59
79
62
86
Creatinine
clearance
(Ml/S)
167
300
1117
183
350
383
245
217
Serum
creatinine1)
Omol/l)
362.4
459.7
114,9
371.3
176.8
194.5
194.5
150.3
Freep- Pancreatic Lundh test3)
amino- function (Trypsin,
benzoic test2 ) μιηοΐ H*/l · s)
acid
(p-aminobenzoic acid
excretion as % of the
applied dose)
15.8 14.0 295.8
27.0 25.8 175.0
44.8 66.8
27.7 22.1 204.2
18.0 18.8 145.8
18.8 8.2 241.7
21.7 12.9
52.5 37.3
Diagnosis
Interstitial bacterial
nephritis
Chronic sclerosing
intracapillary
glomeru lonephrit is
Acute exudative
glomeru lonephrit is
Chronic interstitial
nephritis
Interstitial toxic
nephritis
Chronic interstitial
nephritis
Interstitial toxic
nephritis
Chronic interstitial
nephritis
1) normal < 105/imol/l
2) normal> 47%
3) normal > 147 μπιοί Η VI · s, borderline 100-147 μπιοί H*/l · s, abnormal < 100 μιηοΐ Η ""/l · s
Tab. 3. Results of the oral pancreatic function test and the Lundh test in control patients with normal renal function.
Name
Sch. J.
S.J.
B.E.
F. K..
L. T.
N. A.
U.F.
B. J.
W. S.
H. B.
L. H.
G. H.
K.H.
Sex
d
c5
d
9
9
c5
d
<5
<5
9
9
<$
d
Age
(a)
74
71
50
75
57
57
70
29
31
69
51
52
68
Serum creatinine1)
(μιηοΐ/ΐ)
79.6
53.0
79.6
97.2
70.7
79.6
106.1
97.2
61.9
53.0
79.6
53.0
70.7
Pancreatic
function test
(p-aminobenzoic
acid excretion
as % of the
applied dose)
62.6
73.0
54.3
58.6
68.6
71.9
57.2
57.0
49.4
78.6
56.2
62.4
61.0
Lundh test3)
(Trypsin,
μπιοί Η VI -s)
383.3
179.2
366.7
295.8
295.0
313.3
308.3
258.3
412.5
154.2
191.7
195.8
208.3
Diagnosis
Bronchial carcinoma
Tuberculosis
Irritable colon
Nontropical sprue
Duodenal ulcer
Dumping syndrome
Hyperlipemia
Gastric ulcer
Trauma of pancreas
Cholelithiasis
Hyperthyreodism
Peritoneal carcinosis
Choledochal stenosis
!) normal < 105 μπιοΙ/1
3) normal > 147 μηιοί H*/l · s, borderline 100-147 μπιοί H*/l · s, abnormal < 100 μπιοί Η+/1 · s
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Blood chemistry studies
The biochemical investigations in the blood were performed on
a Technicon SMA Multi-Channel-Analyzer (Technicon, Tarry-
town, New York) in the Chemical Laboratory of the Kantons-
spital Basel, except for serum glucose (13), serum amylase (14),
and urine lactate dehydrogenase (15).
Statistics
The statistical evaluation of the results was carried out with the
aid of Student's t-test and regression analysis according to
methods described by Remington & Shork (16).
Results
Acute toxicity
of N-benzoyl-I-tyrosyl-p-aminobenzoic acid
Clinical aspects
The results of the pancreatic function test and the
Lundh test are shown in table 1. The Lundh test could
not be performed in three of the test subjects for
technical reasons. The interval between the Lundh test
and the pancreatic function test was greater than 4
weeks in three test subjects. One Lundh rest result was
below the lower normal limit (58.3 μτηοΐ H+/l · s). The
pancreatic function test revealed an excretion of p-aminp-
benzoic acid within the normal range in this subject. The
laboratory, clinical, and case history findings gave no
indication of pancreatic disease. The test subjects were
well at the time of the Lundh test, pancreatic function
test and the venipuncture.
Blood and urine tests in the pancreatic function test
For technical reasons it was impossible to evaluate the
prothrombin time in more than nine subjects. One sub-
ject was suspected ofhwingMeulengrachfs disease
because of increase in bilirubin with normal alkaline
phosphatase and serum transaminases (table 1, No 20).
The bilirubin value of this subject was not used.
None of the changes of the observed serum parameters
went beyond the normal range. In the case of the serum
parameters in which significant changes could be seen
between the individual venipunctures, the serum values
of the "controls" were also examined for such differ-
ences, which, except in the case of the transaminases,
were found.
The results of the urine studies showed no indications of
pathological changes. The sediment findings in particular
were always stable. One individual displayed a urine
lactate dehydrogenase value in excess of 60IU/1 in the
first control (6-hour portion). The values during the
subsequent investigations were in the normal, range.
Effect of the renal function
on the pancreatic function test
The results of the investigations with free p-amino-
benzoic acid, N-benzoyl-Z,-tyrosyl-p-aminobenzoic acid,
and the results of the Lundh test, the diagnoses and
values of serum creatinine and creatinine clearance of
the eight patients are summarized in table 2. The excre-
tion of p-aminqbenzoic acid after ingestion of the pep-
tide was markedly reduced in all patients with severely
restricted renal function and correspondingly increased
serum creatinine value. The pancreatic function test
was in the normal range in all control patients with
creatinine values between 53.0 and 106.1 μηιοΐ/ΐ
(tab. 3).
A highly significant correlation existed between the
serum creatinine value and the excretion of p-amino-
benzoic acid after ingestion of the peptide, if renal in-
sufficiency patients and control patients were considered
together (r = 0.81; ρ < 0.001). No definite correlation
could be seen in the latter group alone.
In four of the eight patients with renal insufficiency
the excretion rate of p-aminobenzoic acid was not
clearly different whether ingested in the free or con-
jugated form (tab. 2). Similar results were obtained by
B rnschein et al. (8) in subjects with normal renal func-
tion.
Discussion
Investigation of the toxicity of
N-benzoyl-Z,-tyrosyl-p-aminobenzoic acid
In order to study possible acute toxic effects of
N-benzoyl-i-tyrosyl-p-airiinobenzoic acid, serum and
urine parameters in healthy young test subjects were
checked for significant changes. On the whole these
parameters fell within the normal range, even though
they varied within this range. All of the serum para-
meters, in which significant changes occurred between
the individual venipunctures, were compared with the
serum parameters (first and second venipunctures) of
the "controls". This comparison revealed that the in-
creasing and decreasing trends of the laboratory values
in the two groups compared were always parallel. There-
fore it can be assumed that the changes after 6 hours
are mostly due to liquid intake alone. Only the trans-
aminase values displayed a contrary trend. Between the
first arid second venipunctures the serum glutarhate-
oxalacetate transaminase decreased significantly in the
test subjects, while it did not change in the "controls".
However, one should keep in mind that these changes
vary within the normal range. The question of the
extent to which daily fluctuations in fasting individuals
come into play must remain unanswered, since reports
in this connection are available only with respect to
longer periods of abstinence of nutrients (17).
Clinical side effects were never observed during the
studies with pancreatic function test. No symptoms
related to the gastrointestinal tract or central nervous
system were reported.
Toxic effects of p-aminpbenzoic acid and its metabolites
are rarely mentioned in the literature, but have been
described for doses several times higher than those used
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in the pancreatic function test. p-Aminobenzoic acid
has been used in rickettsiosis (1-4 g/24 hours) (18)
and lupus erythematosus. At dosages which produced
blood concentrations up to a maximum of 600-
700 mg/1, nausea, vomiting, pruritus, and possible
hepatitis were observed. In addition p-aminobenzoic
acid caused hypoglycemic effects in patients on re-
stricted diet, and was followed by leukopenia and
agranulocytosis in some cases (18). Since only an equi-
valent of 320 mg of p-aminobenzoic acid is administered
in the pancreatic function test, such side effects would
scarcely be anticipated. The leukocyte count never
changed significantly during the course of the investiga-
tion.
These data confirm the previous observations of our
and Bornschein's group (7, 8) revealing no toxicity of
N-benzoyl-L-tyrosyl-p-aminobenzoicacid.
Effect of renal function
on the pancreatic function test
In patients with known chronic renal insufficiency of
varying extent, but with intact pancreas function, it
was possible to show that the excretion of p-amino-
benzoic acid is falsely low in the pancreatic function
test. The results in controls and patients with renal
disease show that the diagnostic value of the pancreatic
function test decreases when serum creatinine values
exceed 114.9 μπιοΐ/ΐ. Since the anticipated increase of
p-atninobenzoic acid excretion after administration of
free as opposed to conjugated p-aminobenzoic acid
occurred in only half of the patients with renal in-
sufficiency, such a ratio cannot be utilized to make the
test applicable for patients with renal disease. It appears
that adequate renal function is a prerequisite to
employment of this test.
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